A multicenter, randomized, and double-blind phase IV clinical trial to compare the efficacy and safety of fixed-dose combinations of amlodipine orotate/valsartan 5/160 mg versus valsartan/hydrochlorothiazide 160/12.5 mg in patients with essential hypertension uncontrolled by valsartan 160 mg monotherapy

Samankaltaisia teoksia

• Valsartan 160 mg/Amlodipine 5 mg Combination Therapy versus Amlodipine 10 mg in Hypertensive Patients with Inadequate Response to Amlodipine 5 mg Monotherapy
  Tekijä: Sung, Jidong, et al.
  Julkaistu: (2016)
• The combination of amlodipine/valsartan 5/160 mg produces less peripheral oedema than amlodipine 10 mg in hypertensive patients not adequately controlled with amlodipine 5 mg
  Tekijä: Schrader, J, et al.
  Julkaistu: (2009)
• Real-world effectiveness of amlodipine/valsartan and amlodipine/valsartan/hydrochlorothiazide in high-risk patients and other subgroups
  Tekijä: Assaad-Khalil, Samir Helmy, et al.
  Julkaistu: (2015)
• Triple combination therapy with amlodipine, valsartan, and hydrochlorothiazide vs dual combination therapy with amlodipine and hydrochlorothiazide for stage 2 hypertensive patients
  Tekijä: Destro, Maurizio, et al.
  Julkaistu: (2010)
• Role of valsartan, amlodipine and hydrochlorothiazide fixed combination in blood pressure control: an update
  Tekijä: Destro, Maurizio, et al.
  Julkaistu: (2010)